hemotune raises CHF 5.1 million Series A funding
12.08.2020
OCCIDENT with participation of the Korean medical device company Green Cross Medical Science Corp. (GCMS), and Zürcher Kantonalbank led the investment in the ETH Zurich Spinoff.
 Hemotune Team
|
 |
hemotune AG, currently incubated at Wyss Zurich, today announced the closing of a CHF 5.1 million Series A to advance the development of HemoSystem, a breakthrough blood purification platform based on nanoengineered magnetic beads. Despite the corona crisis, hemotune managed to build a very strong consortium led by OCCIDENT with participation of the Korean medical device company Green Cross Medical Science Corp. (GCMS), and Zürcher Kantonalbank.
The Zurich-based startup received CHF 130.000 support from Venture Kick in 2017.
The Zurich-based startup received CHF 130.000 support from Venture Kick in 2017.